Ferhanoglu, A. B. Et Al. 2017. Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience. 59th Annual Meeting of the American-Society-of-Hematology (ASH) , (Georgia, United States Of America).

Ferhanoglu, A. B., ÖZBALAK, M. M., SALİHOĞLU, A., Soysal, T., Karadogan, I., Paydas, S., ... Ozdemir, E.(2017). Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience . 59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America

Ferhanoglu, A. Et Al. "Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience," 59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 2017

Ferhanoglu, A. B. Et Al. "Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience." 59th Annual Meeting of the American-Society-of-Hematology (ASH) , Georgia, United States Of America, 2017

Ferhanoglu, A. B. Et Al. (2017) . "Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience." 59th Annual Meeting of the American-Society-of-Hematology (ASH) , Georgia, United States Of America.

@conferencepaper{conferencepaper, author={A. Burhan Ferhanoglu Et Al. }, title={Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience}, congress name={59th Annual Meeting of the American-Society-of-Hematology (ASH)}, city={Georgia}, country={United States Of America}, year={2017}}